OncoMatch/Clinical Trials/NCT06195709
ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients
Is NCT06195709 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Endocrine therapy and Endocrine therapy combined with the local treatment of FES-negative lesions for breast carcinoma.
Treatment: Endocrine therapy · Endocrine therapy combined with the local treatment of FES-negative lesions · Chemotherapy — Eclectic is a strategy trial; once the class of treatment (endocrine therapy or chemotherapy) has been allocated according to 16α-18F-fluoro-17β-oestradiol (18F-FES) Positron Emission Tomography/Computed Tomography (PET/CT) results and circulating tumor biomarkers, clinicians will decide which treatment to use.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Breast Carcinoma
Biomarker criteria
Required: ESR1 overexpression (ER-positive, ≥10%) (≥10%)
Estrogen Receptor (ER)-positive (≥10%)
Required: HER2 (ERBB2) negative
HER2-negative (ASCO/College of American Pathologists guidelines)
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: aromatase inhibitor — first line, metastatic
disease has progressed on first line endocrine therapy with aromatase inhibitor
Must have received: CDK4/6 inhibitor — first line, metastatic
disease has progressed on first line endocrine therapy with...CDK4/6 inhibitor
Cannot have received: chemotherapy
One or more prior line of chemotherapy in the metastatic setting [excluded]
Cannot have received: systemic treatment (other than first line aromatase inhibitor and CDK4/6 inhibitor)
Any other systemic treatment given at metastatic disease than the first line therapy with aromatase inhibitor and CDK4/6 inhibitor [excluded]
Cannot have received: estrogen receptor degrader (fulvestrant, oral SERDs, PROTAC)
Prior exposure to any authorized or experimental agent degrading the estrogen receptor (fulvestrant, oral SERDs, PROTAC, etc) [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06195709 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior chemotherapy, systemic treatment (other than first line aromatase inhibitor and CDK4/6 inhibitor), estrogen receptor degrader disqualifies patients from enrollment.
Does this trial require ESR1?
Yes, ESR1 overexpression (ER-positive, ≥10%) is a required biomarker for enrollment.
Does this trial require ERBB2?
Yes, ERBB2 negative is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages